Evaluating equitable care in the ICU: Creating a causal inference framework to assess the impact of life-sustaining interventions across racial and ethnic groups

RUNNING TITLE: Causal inference framework in sepsis

Author List:

Tristan Struja, MD, MSc, MPH, tstruja@mit.edu – 2, 4* João Matos, MSc, jcmatos@mit.edu – 2, 5* Barbara Lam, MD, barbaradlam@gmail.com – 11 Yiren Cao, irene.yiren.cao@gmail.com – 3 Xiaoli Liu, PhD, xiaoliliubuaa@gmail.com - 8, 2 Yugang Jia, PhD, MPH, yugang@verily.com – 2 Christopher M. Sauer, MD MPH PhD, sauerc@mit.edu - 2,9,10 Helen D'Couto, MD, hdcouto@bidmc.harvard.edu – 1 Irene Dankwa-Mullan, MD MPH, idankwamullan@gmail.com – 7 Leo Anthony Celi, MD, MS, MPH, Iceli@mit.edu – 1, 2, 3 Andre Kurepa Waschka, PhD, waschka_ak@mercer.edu – 6

* equally first authors

Author Affiliations:

- 1. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
- 2. Laboratory for Computational Physiology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA
- 3. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- 4. Medical University Clinic, Kantonsspital Aarau, Aarau, Switzerland
- 5. Faculty of Engineering of University of Porto, Porto, Portugal
- 6. Mercer University, Macon, GA, USA
- 7. Milken Institute School of Public Health, The George Washington University, Washington DC, USA
- 8. Center for Artificial Intelligence in Medicine, The General Hospital of PLA, Beijing, China
- 9. Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Germany
- 10. Institute for Artificial Intelligence in Medicine, University Hospital Essen, Germany
- 11. Department of Medicine, Division of Hematology and Oncology and Division of Clinical Informatics, Beth Israel Deaconess Medical Center, Boston, MA, USA

1

Corresponding Author:

Tristan Struja, MD, MSc, MPH, ORCID 0000-0003-0199-0184 Email: tstruja@mit.edu Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, MA, USA

ACKNOWLEDGEMENT

Guarantor: Struja

Author Contributions: Dr Struja and Mr. Matos designed the study and had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Struja, Celi, Matos, Jia, and Waschka.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Struja.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Struja, Cao, Waschka, and Matos.

Administrative, technical, or material support: Celi, Jia, and Waschka.

Supervision: Celi, Jia, and Waschka.

Conflict of Interest Disclosures: All authors confirm that they do not have a conflict of interest associated with this manuscript. YC and YJ are currently also affiliated with Verily life science, SSF, CA.

Funding/Support: This study was supported by unrestricted educational grants to Celi (NIBIB, R01 EB001659), Struja (Swiss National Science Foundation, P400PM_194497 / 1), Matos (Fulbright / FLAD Grant, Portugal, AY 2022/2023), and Sauer (German Research Foundation funded UMEA Clinician Scientist Program, FU356/12-2).

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Manuscript Information

Abstract word count: 269 (max. 300) Manuscript word count: approx. 2,698 (max. 3,200) Number of tables: 1; Number of figures: 4 Key words: Sepsis, TMLE, MIMIC-IV, Outcomes Assessment, Health Services, Critical Care, Health discrepancies Version: July 14, 2023 Supplementary material: 4 tables, 3 figures

Availability of data: The data that support the findings of this study are available in MIMIC-IV with the identifier <u>doi.org/10.1093/jamia/ocx084</u>. The database is publicly available on PhysioNet.

Code availability: The code that produces the results in this manuscript can be accessed at https://github.com/joamats/mit-tmle-sepsis, which includes detailed instructions for running the code.

ABSTRACT

Background: Variability in the provision of intensive care unit (ICU)-interventions may lead to disparities between socially defined racial-ethnic groups.

Research Question: We used causal inference to examine the use of invasive mechanical ventilation (IMV), renal replacement therapy (RRT), and vasopressor agents (VP) to identify disparities in outcomes across race-ethnicity in patients with sepsis.

Study Design and Methods: Single-center, academic referral hospital in Boston, Massachusetts, USA. Retrospective analysis of treatment effect with a targeted trial design categorized by treatment assignment within the first 24 hours in the MIMIC-IV dataset (2008-2019) using targeted maximum likelihood estimation. Of 76,943 ICU stays in MIMIC-IV, 32,971 adult stays fulfilling sepsis-3 criteria were included. The primary outcome was in-hospital mortality. Secondary outcomes were hospital-free days, and occurrence of nosocomial infection stratified by predicted mortality probability ranges and self-reported race-ethnicity. Average treatment effects by treatment type and race-ethnicity, Racial-ethnic group (REG) or White group (WG), were estimated.

Results: Of 19,419 admissions that met inclusion criteria, median age was 68 years, 57.4% were women, 82% were White, and mortality was 18.2%. There was no difference in mortality benefit associated with the administration of IMV, RRT, or VP between the REG and the WG. There was also no difference in hospital-free days or nosocomial infections. These findings are unchanged with different eligibility periods.

Interpretation: There were no differences in the treatment outcomes from three life-sustaining interventions in the ICU according to race-ethnicity. While there was no discernable harm from the treatments across mortality risk, there was also no measurable benefit. These findings highlight the need for research to understand better the risk-benefit of life-sustaining interventions in the ICU.

INTRODUCTION

Researchers have repeatedly discovered racial and ethnic disparities in critical illness and endof-life care ^{1,2}. An analysis of over 1,000 patients with a history of stroke showed that black patients in the cohort were less likely than white patients to use hospice and more likely to have multiple emergency department visits, hospitalizations, and intensive treatments in their last six months of life ³. While the hypothesized reasons for these types of findings are multifactorial, disparities in who receives life-sustaining treatments have also raised the question of subconscious and systemic biases ¹. In a study of over 17,000 intensive care unit (ICU) admissions, white patients received more technological monitoring, laboratory testing, and life-supporting treatments compared to black patients on the first day of their ICU stay ⁴. Another study of over 28 hospitals in the United States showed that black patients with pneumonia were less likely to receive guideline-adherent antibiotics and more likely to receive mechanical ventilation ⁵. These disparities were highlighted during the COVID-19 pandemic when researchers found that there were not only differences in interventions across racial and ethnic groups ⁶, but also in survival outcomes ^{7,8}.

Uncovering disparities in care is more urgent than ever given the rising popularity of artificial intelligence (AI) technology. Now, disparities have the opportunity to cause harm twice: their existence can drive inequities in care today and perpetuate bias in AI algorithms tomorrow ⁹. Conducting randomized controlled trials (RCTs) to understand how life-sustaining interventions might lead to different outcomes across racial and ethnic groups is both unethical and impracticable. These types of research questions are best answered using observational data, but there are limitations to databases such as claims registries, which often lack important clinical details ^{10,11}. With the development of high-resolution datasets such as MIMIC-IV, we can apply a causal inference framework to leverage this real-world data in understanding how different patients have been affected by different interventions ¹².

In this study, we provide a causal inference framework for assessing the impact of life-sustaining interventions across different racial and ethnic groups in the MIMIC-IV database. MIMIC-IV is one of the most widely used datasets in both critical care and machine learning research; it is therefore imperative that we understand what potential biases exist in the data. We also provide the code for our framework so that other groups can readily assess for potential inequities in critical care at their own organizations.

METHODS

This study is reported in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement ¹³. The language of this paper follows the American Medical Association's reccomendations ¹⁴. Data were extracted from the open-access and deidentified MIMIC-IV using Google's BigQuery software. MIMIC is maintained by the Laboratory for Computational Physiology at Massachusetts Institute of Technology (MIT) ¹⁵. Approval for the study and a waiver of consent was obtained from the Institutional Review Boards as all the data is de-identified. MIMIC-IV includes physiologic data collected from bedside monitors, as well as other clinical variables and provider documents recorded in the ICU electronic medical record. Approximately 70,000 de-identified medical ICU records are archived in MIMIC-IV.

We hypothesized that treatment allocation of ICU interventions is not equally distributed across race-ethnicity leading to differences in outcomes. We suspected that Racial-ethnic patient group with sepsis experienced a more harmful use of ICU interventions, especially in less severely ill patients.

Cohort Selection

All patients older than 18 years of age who had sepsis as defined by the sepsis-3 criteria were included in the analysis ¹⁶. We only included first-time ICU stays, and excluded cases missing race or ethnicity information or discharge location. This also includes patients with race "other" as this category can comprise patients of all ethnicities. Patients were excluded if they had a length of stay (LOS) of less than one day or more than 30 days to ensure a homogenous cohort. To avoid immortal time bias, treatment assignment was only possible during an eligibility period of the first 24 hours for invasive mechanical ventilation (IMV) and vasopressors (VP), and first three days for renal replacement therapy (RRT). Immortal time bias occurs in observational studies when there is failure to align start of follow-up, specification of eligibility, and treatment assignment leading to a time window during the study where, for inclusion in the cohort, the patients are required to be *immortal* to the event of interest ¹⁷. It can lead to erroneous conclusions about the effectiveness of treatments or interventions if not properly accounted for in the study design and analysis. If treatment was started after this eligibility period the patient was retained in the control group, emulating a targeted trial (see **eTable 1**).

Covariates

Patient-level variables were obtained from the database at the time of ICU admission and timevarying variables were aggregated for the first 24 hours of the stay by taking the maximum, minimum, or mean value as appropriate (see **eTable 2**). We further extracted ICD-10 codes for key comorbidities, including hypertension, COPD, asthma, heart failure, stages of chronic kidney disease (CKD), and Oxford Acute Severity of Illness Score (OASIS). Patients with a label for White (e.g., White, White – Brazilian, White – Russian) were grouped as White (WG), while we grouped the remainder as Racial-ethnic patient group (REG) as race-ethnicity is heavily imbalanced in MIMIC (i.e., approximately 80% White patients).

ICU admission OASIS scores were used to calculated predicted mortality probability (PMP) to give an easily generalizable and externally valid scale ¹⁸⁻²⁰. Patients were categorized in PMP quartiles as having low, moderate, high, or very high sepsis severity.

Outcomes

The primary outcome was in-hospital mortality, including discharge to hospice care. Secondary outcomes were hospital-free days by day 28 and combined nosocomial infection (central-line associated bloodstream infection, catheter associated urinary tract infection, surgical site infection, and ventilator associated pneumonia). In line with recent research, we used the time of discharge or death at an odd versus an even hour as a negative control outcome ²¹, as treatment should not affect this random event.

Statistical Analysis

Statistical analysis was performed using *R* version 4.2²² and *Python* 3.10²³ running on Visual Studio Code. We used targeted maximum likelihood estimation (TMLE) models adjusted for confounders to compute the average treatment effect (ATE) for each of the interventions, stratified by race-ethnicity and predicted mortality range ²⁴. TMLE is a semiparametric framework estimating the causal effect of an intervention on an outcome of interest. For counterfactual modelling, we used the *SuperLearner* package, an ensemble machine learning algorithm with 5-fold cross-validation. The ATE is a marginal effect, meaning it is averaged over the covariates. ATE is defined as the difference in outcome should everyone be treated with the invasive treatment versus no one being treated, as shown in equation 1:

$$ATE = E[E[Y | A = 1, W] - E[Y | A = 0, W]], \quad (eq. 1)$$

Where Y represents the outcome (primary: in-hospital mortality; secondary: hospital-free days by day 28 and combined nosocomial infections; negative control: death or discharge at odd hour); A the treatment (IMV, RRT, or VP); and W the confounders for adjustment.

Treatment assignment was assumed to be independent of the outcome (i.e., conditional exchangeability assumption). There were no multiple versions of a treatment, as we dichotomized all treatments (i.e., consistency assumption). We tabulated the treatments according to raceethnicity and predicted mortality range to check whether all strata were eligible to receive a treatment (i.e., positivity assumption).

In a sensitivity analysis, we repeated the calculations changing the eligibility period for RRT from 3 days to 1 day or 5 days. We consider our work hypothesis generating, which is why we abstained from computing p-values and only provided 95% confidence intervals.

RESULTS

After applying our inclusion and exclusion criteria, we were left with a sample size of 19,419 admissions (see **Figure 1**). **Table 1** shows the baseline characteristics of our cohort stratified by race-ethnicity. Median age was 68 years, 57.4% were women, 82% were White. Median length of stay (LOS) was 9.5 days and did not differ substantially if patients survived or died. 18.2% of patients admitted to an ICU died or were discharged to a hospice (2.7% of all discharges). Baseline Charlson comorbidity index (CCI), IMV, and VP use, OASIS and SOFA scores between races and ethnicities were evenly balanced. However, there were marked differences in the use of RRT (11.2% in the REG, 6.1% in the WG), in prevalence of hypertension, CKD, and age (median age 64.5 in the REG, 69 in the WG). All race-ethnicity groups and treatments had a non-zero probability of occurring in each of the predicted mortality categories showing no indication for violation of the positivity assumption (see **eTable 3**).

Unadjusted Analysis: Primary Outcome

We started by analyzing the unadjusted probability of a patient receiving a treatment, should they died or survived, to identify initial patterns in the data and check consistency of TMLE analysis. In patients receiving IMV and VP, the proportion of patients to survive the treatment was consistently higher than dying on treatment, albeit differences diminished with increasing illness severity (see **Figure 2**). In patients receiving RRT, the proportion for patients surviving with treatment was consistently lower than dying on treatment. These trends were consistent when stratifying by race-ethnicity (see **Figure 1**).

TMLE: Negative Control Outcome

In adjusted TMLE modeling, there was no treatment effect in any intervention when discharge or death at an odd hour was used as a negative control outcome (see **eTable 4** and **Figure 3**). This suggests that residual confounding has been mitigated in our study ²¹.

TMLE: Primary Outcome

We saw no clear distinction between the two racial groups for in-hospital mortality in any of the treatments (see **Figure 4** and **eTable 4**). In patients receiving IMV and VP, the confidence intervals for the ATE were crossing the null, except for the WG in the predicted mortality range of 0-6% and 12-21%. For patients under RRT, there was a consistent signal for harm in the lowest predicted mortality range of 0-6% with an ATE of 6.0% (95% CI 5.0%-7.0%) in the WG and ATE of 5.0% (95% CI 2.0%-7.0%) in the REG, but not in higher predicted mortality ranges. Results

were similar in sensitivity analysis with RRT eligibility periods of 1 day or 5 days instead of 3 days (see **eFigure 2**).

TMLE: Secondary Outcomes

Hospital-free days were similar between the two racial groups, except for patients on RRT in the highest predicted mortality range >21% where we observed an ATE of 1.39 mean days (95% CI 0.66 to 2.12) in the REG and -0.4 mean days (95% -0.77 to -0.04) in the WG (see **eTable 4** and **eFigure 3**). Both groups had fewer hospital-free days when subjected to IMV, whereas VP did not influence the outcome. For the outcome of combined nosocomial infection, we consistently saw an ATE of 0% across all treatments and predicted mortality ranges.

DISCUSSION

Using a causal inference framework to assess critically ill patients with sepsis in the MIMIC-IV database, we found no racial-ethnic disparities in the outcomes of patients treated with IMV, RRT, and VP. We also provide an open-source causal inference analytic pipeline that researchers can use to perform disparity research using electronic health record data.

Health equity is increasingly recognized by policymakers as essential to public health ^{25,26}. In December of 2022, the Center for Medicare and Medicaid Services (CMS) proposed tying reimbursements to health equity outcomes ²⁷, highlighting the importance of organizations having a way to measure health equity. The Centers for Disease Control and Prevention (CDC) cites measurement as one of the key pillars of advancing health equity, alongside population-level strategies and policy changes ²⁸. Several frameworks have been proposed for describing the social determinants of health that lead to disparities ^{29,30}, but organizations need an out-of-thebox tool they can easily and repeatedly use to assess measure health equity. Causal inference on high-resolution electronic health record data offers a robust method of detecting test and treatment disparities that are not explained by clinical factors and if present, quantifying their effect sizes on patient outcomes. We employed TMLE to investigate whether outcomes from IMV, RRT and VP vary across race-ethnicities after adjusting for time-varying clinical confounding, and our proposed framework is both free and easy to use, and can be run on a personal computer. TMLE is a semiparametric estimator offering several compelling properties. It is based on the targeted minimum loss-based estimation and machine learning algorithms to minimize the risk of model misspecification ³¹. As TMLE is doubly robust, if either the outcome regression or the exposure mechanism is consistently estimated, it will yield unbiased estimates, and when both the treatment and exposure are estimated consistently, the TMLE estimator is asymptotically efficient. Additionally, its estimates will always stay within the bounds of the original outcome, thus making it more robust to outliers and spare data resulting in more reliable results. Finally, since TMLE fully incorporates machine learning, it is also a very attractive choice for analyzing complex observational data with a large number of variables and potentially complex relationships ³². While TMLE offers the most mature package for R users, researchers could also use one of the many causal inference packages available in python ³³.

Assessing data for potential disparities is also important as datasets are increasingly utilized to build AI algorithms. Major companies including Google, Microsoft, and PwC have acknowledged that causal inference is an important framework for reviewing data and have updated their software packages to include tools for counterfactual modeling ³⁴⁻³⁶. Our open-source causal inference analytic pipeline is important not just for hospital quality metrics but also for researchers to identify biases in their datasets prior to developing models for prediction, classification and optimization.

Interestingly, our analysis found that all three of the treatments we assessed—IMV, RRT, and VP—did not lead to significant benefit in mortality outcomes across all race-ethnicities. There was a signal for potential harm in some patients treated with RRT, suggesting that critically ill patients may benefit while less ill patients may be harmed. Several recent study findings have shown that a "less is more" strategy may be beneficial in critical care ³⁷ and further research is needed to understand which populations benefit most from life-sustaining interventions. This was beyond the scope of our current study, but sharing our repository publicly allows our analysis to be replicated and extended by researchers interested in exploring this question.

Limitations

One of the limitations to our study is the categorization of patients into two broad racial-ethnic groups. We used this strategy due to the effective sample size once analysis is stratified across illness severity. In addition, the goal of this study was to demonstrate a framework for evaluating health disparities regardless of the axis of demography being investigated. Important differences in culture, ancestry, and lived experiences are lost when patients are aggregated into less precise groups, whether the comparison is for white vs. non-white, binary vs. non-binary, low- vs. high-income. Although we found no striking differences in treatments and outcomes between our two groups, disparities may be present in smaller subgroup analyses if the sample size had been larger. Even though MIMIC-IV contains 76,943 ICU stays and delineates 33 options for the race and ethnicity categories, power was not be enough to draw causal inferences on subpopulations. Furthermore, 17% (i.e., 3,983 out of 23,401) of patients in the dataset are categorized as "other," highlighting the challenges of acquiring accurate demographic data at the bedside, particularly in a critically ill population. Further diversity, equity, and inclusion (DEI) efforts are needed at both the institutional and research level to improve our ability to collect and analyze disaggregated racial ethnic data ³⁸. Other subgroup analyses, such as evaluating differences in treatments and

outcomes across sex and gender identity, preferred language, and education and health literacy can also add to our understanding of how social determinants of health may lead to disparities.

CONCLUSIONS

Causal inference enables us to explore the sources and drivers of disparities in healthcare, providing an opportunity for equality improvement initiatives or mitigate bias in AI algorithms. We provide an open-source analytic framework that allows healthcare providers, researchers, and policy makers to leverage a causal inference framework for health disparity and data science research.

REFERENCES

- 1. Soto GJ, Martin GS, Gong MN. Healthcare disparities in critical illness. *Critical care medicine*. 2013;41(12):2784-2793.
- 2. Johnson KS. Racial and ethnic disparities in palliative care. *J Palliat Med.* 2013;16(11):1329-1334.
- 3. Ornstein KA, Roth DL, Huang J, et al. Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort. *JAMA Netw Open.* 2020;3(8):e2014639.
- 4. Williams JF, Zimmerman JE, Wagner DP, Hawkins M, Knaus WA. African-American and white patients admitted to the intensive care unit: is there a difference in therapy and outcome? *Critical care medicine*. 1995;23(4):626-636.
- 5. Mayr FB, Yende S, Linde-Zwirble WT, et al. Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis. *JAMA*. 2010;303(24):2495-2503.
- 6. Nguyen KH, Thorsness R, Hayes S, et al. Evaluation of Racial, Ethnic, and Socioeconomic Disparities in Initiation of Kidney Failure Treatment During the First 4 Months of the COVID-19 Pandemic. *JAMA Netw Open.* 2021;4(10):e2127369.
- 7. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. *EClinicalMedicine*. 2020;29:100630.
- 8. Magesh S, John D, Li WT, et al. Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Meta-analysis. *JAMA Netw Open*. 2021;4(11):e2134147.
- 9. Nicoletti L, Bass D. Humans are biased. Generative AI is even worse. 2023. <u>https://www.bloomberg.com/graphics/2023-generative-ai-bias/?srnd=graphics-</u> <u>v2&utm_source=www.healthcareainews.com&utm_medium=newsletter&utm_campaign</u> =healthcare-s-hidden-gold. Accessed June 16, 2023.
- 10. Martino S, Elliott M, Haas A, et al. Trends in Racial, Ethnic, Sex, and Rural- Urban Inequities in Health Care in Medicare Advantage: 2009–2018. 2021. https://www.cms.gov/files/document/trends-inequities-medicare-advantage-2009-2018.pdf.
- 11. Desai RJ, Matheny ME, Johnson K, et al. Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. *NPJ Digit Med.* 2021;4(1):170.
- 12. Pirracchio R, Hubbard A, Sprung CL, Chevret S, Annane D, Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis C. Assessment of Machine Learning to Estimate the Individual Treatment Effect of Corticosteroids in Septic Shock. *JAMA Netw Open.* 2020;3(12):e2029050.
- 13. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med.* 2007;4(10):e296.
- 14. Colleges AMAaAoAM. Advancing Health Equity: Guide on Language, Narrative and Concepts. Vol 21:587460:pdf:10/21: American Medical Association; 2021:54.
- 15. Goldberger AL, Amaral LA, Glass L, et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. *Circulation*. 2000;101(23):E215-220.
- 16. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-810.
- 17. Vail EA, Gershengorn HB, Wunsch H, Walkey AJ. Attention to Immortal Time Bias in Critical Care Research. *Am J Respir Crit Care Med.* 2021;203(10):1222-1229.

- 18. Ladha KS, Zhao K, Quraishi SA, et al. The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients. *BMJ open.* 2015;5(9):e008990.
- 19. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med.* 1996;22(7):707-710.
- 20. Johnson AE, Kramer AA, Clifford GD. A new severity of illness scale using a subset of Acute Physiology And Chronic Health Evaluation data elements shows comparable predictive accuracy. *Critical care medicine*. 2013;41(7):1711-1718.
- 21. Bosch NA, Teja B, Law AC, Pang B, Jafarzadeh SR, Walkey AJ. Comparative Effectiveness of Fludrocortisone and Hydrocortisone vs Hydrocortisone Alone Among Patients With Septic Shock. *JAMA Intern Med.* 2023;183(5):451-459.
- 22. Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022.
- 23. *Python reference manual* [computer program]. Centrum voor Wiskunde en Informatica Amsterdam; 1995.
- 24. Gruber S, Laan MJvd. tmle: AnRPackage for Targeted Maximum Likelihood Estimation. *Journal of Statistical Software.* 2012;51(13).
- 25. Services USDoHaH. Health Equity and Health Disparities Environmental Scan. 2022. <u>https://health.gov/sites/default/files/2022-04/HP2030-</u> <u>HealthEquityEnvironmentalScan.pdf</u>.
- 26. Team SDoHW. World Health Day 2021: It's time to build a fairer, healthier world for everyone, everywhere. *Health equity and its determinants.* 2021. https://www.who.int/publications/m/item/health-equity-and-its-determinants.
- 27. Services CfMM. CMS Proposes Policies to Improve Patient Safety and Promote Health Equity. 2023; <u>https://www.cms.gov/newsroom/press-releases/cms-proposes-policies-improve-patient-safety-and-promote-health-equity</u>. Accessed May 29, 2023, 2023.
- 28. Liburd LC, Ehlinger E, Liao Y, Lichtveld M. Strengthening the Science and Practice of Health Equity in Public Health. *J Public Health Manag Pract.* 2016;22 Suppl 1:S1-4.
- 29. Dover DC, Belon AP. The health equity measurement framework: a comprehensive model to measure social inequities in health. *Int J Equity Health.* 2019;18(1):36.
- 30. Health COoM. The CMS Framework for Health Equity (2022-2032). 2022. <u>https://www.cms.gov/about-cms/agency-information/omh/health-equity-programs/cms-framework-for-health-equity</u>.
- 31. van der Laan MJ, Rose S. *Targeted Learning: Causal Inference for Observational and Experimental Data.* Springer New York; 2011.
- 32. Schuler MS, Rose S. Targeted Maximum Likelihood Estimation for Causal Inference in Observational Studies. *Am J Epidemiol.* 2017;185(1):65-73.
- 33. Yao L, Chu Z, Li S, Li Y, Gao J, Zhang A. A Survey on Causal Inference. *ACM Transactions on Knowledge Discovery from Data.* 2021;15(5):1-46.
- 34. Microsoft. Responsible AI. 2023; <u>https://responsibleaitoolbox.ai</u>. Accessed June 16, 2023, 2023.
- 35. PwC. Responsible AI Toolkit. 2023; <u>https://www.pwc.com/gx/en/issues/data-and-analytics/artificial-intelligence/what-is-responsible-ai.html</u>. Accessed June 16, 2023, 2023.
- 36. Google. Tensorflow Responsible AI. 2023; <u>https://www.tensorflow.org/responsible_ai</u>. Accessed June 16, 2023, 2023.
- 37. Auriemma CL, Van den Berghe G, Halpern SD. Less is more in critical care is supported by evidence-based medicine. *Intensive Care Med.* 2019;45(12):1806-1809.

38. Liang PS, Kwon SC, Cho I, Trinh-Shevrin C, Yi S. Disaggregating Racial and Ethnic Data: A Step Toward Diversity, Equity, and Inclusion. *Clin Gastroenterol Hepatol.* 2023;21(3):567-571.

EXHIBITS

<u>Table 1</u>: Baseline information on the study cohort

	Racial-ethnic group (N=3,496)	White group (N=15,923)	Overall (N=19,419)
Racial-ethnic group			-
Asian	659 (18.8%)	0 (0%)	659 (3.4%)
Black	2,027 (58.0%)	0 (0%)	2,027 (10.4%)
Hispanic	810 (23.2%)	0 (0%)	810 (4.2%)
White	0 (0%)	15,923 (100%)	15,923 (82.0%)
In-hospital mortality	664 (19.0%)	2,866 (18.0%)	3,530 (18.2%)
Discharge to hospice	102 (2.9%)	417 (2.6%)	519 (2.7%)
Elective admission	325 (9.3%)	2,740 (17.2%)	3,065 (15.8%)
Vasopressors started in eligibility period	1,337 (38.2%)	7,299 (45.8%)	8,636 (44.5%)
Mechanical ventilation started in eligibility period	1,514 (43.3%)	7,036 (44.2%)	8,550 (44.0%)
Renal replacement therapy started in eligibility period	390 (11.2%)	974 (6.1%)	1,364 (7.0%)
Central line-associated bloodstream infection	3 (0.1%)	11 (0.1%)	14 (0.1%)
Catheter-associated urinary tract infection	4 (0.1%)	17 (0.1%)	21 (0.1%)

	Racial-ethnic group (N=3,496)	White group (N=15,923)	Overall (N=19,419)
Surgical site infection	11 (0.3%)	45 (0.3%)	56 (0.3%)
Ventilator-associated pneumonia	23 (0.7%)	60 (0.4%)	83 (0.4%)
Nosocomial infections combined	39 (1.1%)	125 (0.8%)	164 (0.8%)
Age categorical (years)			
18 - 44	514 (14.7%)	1,206 (7.6%)	1,720 (8.9%)
45 - 64	1,234 (35.3%)	4,943 (31.0%)	6,177 (31.8%)
65 - 74	756 (21.6%)	3,950 (24.8%)	4,706 (24.2%)
75 - 84	638 (18.2%)	3,600 (22.6%)	4,238 (21.8%)
85 and higher	354 (10.1%)	2,224 (13.9%)	2,577 (13.3%)
Age overall (years)			
Median (IQR)	64.5 (52.0, 76.0)	69.0 (59.0, 79.0)	68.0 (57.0, 79.0)
Sex			
Female	1,808 (51.7%)	9,331 (58.6%)	11,139 (57.4%)
Male	1,688 (48.3%)	6,592 (41.4%)	8,280 (42.6%)
OASIS			
Median (IQR)	32.0 (27.0, 39.0)	32.0 (27.0, 38.0)	32.0 (27.0, 38.0)
SOFA score			
Median (IQR)	5.00 (3.00, 8.00)	5.00 (3.00, 8.00)	5.00 (3.00, 8.00)

	Racial-ethnic group (N=3,496)	White group (N=15,923)	Overall (N=19,419)	
Length of stay (days)				
Median (IQR)	9.73 (5.77, 16.8)	9.06 (5.71, 15.6)	9.54 (5.72, 15.7)	
Length of stay, if survived (days)				
Median (IQR)	9.77 (5.85, 17.0)	8.83 (5.76, 15.5)	9.56 (5.78, 15.6)	
Length of stay, if died (days)				
Median (IQR)	9.27 (4.74, 16.2)	9.41 (4.72, 16.6)	9.38 (4.72, 16.6)	
Charlson comorbidity index categorical				
0 - 3	752 (21.5%)	2,966 (18.6%)	3,718 (19.1%)	
4 - 6	1,161 (33.2%)	6,587 (41.4%)	7,748 (39.9%)	
7 - 10	1,279 (36.6%)	5,338 (33.5%)	6,617 (34.1%)	
11 and above	304 (8.7%)	1,032 (6.5%)	1,336 (6.9%)	
Charlson comorbidity index continuous				
Median (IQR)	6.00 (4.00, 8.00)	6.00 (4.00, 8.00)	6.00 (4.00, 8.00)	
Hypertension present	2,424 (69.3%)	10,480 (65.8%)	12,904 (66.5%)	
Congestive heart failure present	1,229 (35.2%)	5,420 (34.0%)	6,649 (34.2%)	
COPD present	809 (23.1%)	3,804 (23.9%)	4,613 (23.8%)	
Asthma present	47 (1.3%)	214 (1.3%)	261 (1.3%)	

	Racial-ethnic group V (N=3,496) (Overall (N=19,419)	
Chronic kidney disease stage ≥ 3 present	670 (19.2%)	1,665 (10.5%)	2,335 (12.0%)	

Legend: Racial-ethnic patient group includes Asian, Black, Hispanic, Latino, etc.

Abbreviations: IQR; interquartile range; COPD, chronic obstructive pulmonary disease; OASIS, Oxford Acute Severity of Illness Score; SOFA, sequential organ failure assessment

Figure 1: Study cohort selection flow chart



Abbreviations: LOS, Length of stay



Figure 2: Distribution of patients across predicted mortality ranges, per invasive treatment.

Abbreviations: RRT, renal replacement therapy

Figure 3: TMLE derived average treatment effects for change in probability of discharge or death at an odd hour vs. even hour of any given day as negative control outcome over predicted mortality categories.



TMLE for odd hour vs. even hour of discharge or death

Abbreviations: ATE, average treatment effects; TMLE, targeted maximum likelihood; RRT, renal replacement therapy

Figure 4: TMLE derived average treatment effects for change in probability of death over predicted mortality categories with RRT eligibility period of 3 days.



TMLE for in-hospital mortality for each invasive treatment

Abbreviations: ATE, average treatment effects; TMLE, targeted maximum likelihood; RRT, renal replacement therapy

Supplementary Material Evaluating equitable care in the ICU: Creating a causal inference framework to assess the impact of life-sustaining interventions across racial and ethnic groups

Author List:

Tristan Struja, MD, MSc, MPH, tstruja@mit.edu – 2, 4* João Matos, BSc, jcmatos@mit.edu – 2, 5* Barbara Lam, MD, barbaradlam@gmail.com – 11 Yiren Cao, irene.yiren.cao@gmail.com – 3 Xiaoli Liu, PhD, xiaoliliubuaa@gmail.com - 8, 2 Yugang Jia, PhD, MPH, yugang@verily.com – 2 Christopher M. Sauer, MD MPH PhD, sauerc@mit.edu- 2,9,10 Helen D'Couto, MD, hdcouto@bidmc.harvard.edu – 1 Irene Dankwa-Mullan, MD MPH, idankwamullan@gmail.com – 7 Leo Anthony Celi, MD, MS, MPH, Iceli@mit.edu – 1, 2, 3 Andre Kurepa Waschka, PhD, waschka_ak@mercer.edu – 6

* equally first authors

Author Affiliations:

- 1. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
- 2. Laboratory for Computational Physiology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA
- 3. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- 4. Medical University Clinic, Kantonsspital Aarau, Aarau, Switzerland
- 5. Faculty of Engineering of University of Porto, Porto, Portugal
- 6. Mercer University, Macon, GA, USA
- 7. Milken Institute School of Public Health, The George Washington University, Washington DC, USA
- 8. Center for Artificial Intelligence in Medicine, The General Hospital of PLA, Beijing, China

- 9. Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Germany
- 10. Institute for Artificial Intelligence in Medicine, University Hospital Essen, Germany
- 11. Department of Medicine, Division of Hematology and Oncology and Division of Clinical Informatics, Beth Israel Deaconess Medical Center, Boston, MA, USA

Corresponding Author:

Tristan Struja, MD, MSc, MPH, ORCID 0000-0003-0199-0184 Email: tstruja@mit.edu Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, MA, USA

Conflicts of Interest:

None of the authors have any conflicts of interest relevant to this work. YC and YJ are currently also affiliated with Verily life science, SSF, CA.

Manuscript Information

Key words: Sepsis, TMLE, MIMIC-IV, Outcomes Assessment, Health Services, Critical Care, Health discrepancies Version: July 14, 2023 Supplementary material: 4 tables, 3 figures

Supplemental Online Content

eTable 1 Comparison between target trial and the observational study of the effectiveness of invasive treatments in patients with sepsis

eTable 2 Variables used in the analysis to adjust the TMLE models

eTable 3 Positivity of mortality for every mortality probability, treatment, and race-ethnicity, to check for violations of the positivity assumption

eTable 4 Primary and secondary outcomes using targeted maximum likelihood estimation

eFigure 1a Distribution of patients across predicted mortality ranges, per invasive treatment for Racial-ethnic group only

eFigure 1b Distribution of patients across predicted mortality ranges, per invasive treatment for White group only

eFigure 2a TMLE derived average treatment effects for change in probability of death over predicted mortality categories with an

eligibility period for RRT of 1 day instead of 3 days

eFigure 2b TMLE derived average treatment effects for change in probability of death over predicted mortality categories with an eligibility period for RRT of 5 days instead of 3 days.

eFigure 3 TMLE derived average treatment effects for change in mean hospital-free days over predicted mortality categories

This supplemental material has been provided by the authors to give readers additional information about their work.

<u>eTable 1</u>: Comparison between target trial and the observational study of the effectiveness of invasive treatments in patients with sepsis (adapted from Hernán MA, NEJM 2021).

Approach	Target Trial	Observational study
Eligibility criteria	Patients with their first stay with least 24 hours stay fulfilling sepsis-3 criteria and ≥18 years of age and known ethnicity	Same as for target trial
Treatment strategies	Initiation of mechanical ventilation, RRT, or vasopressors within the first 24 hours (72 hours for RRT) of ICU admissions	Same as for target trial
Treatment assignment	Intention-to-treat and per-protocol effects without blinding	Based on observed data
Outcomes	Primary: in-hospital death or discharge to hospice Secondary: hospital-free days by day 28, nosocomial infections (CLABSI, CAUTI, SSI, VAP)	Same as for target trial
Follow-up	From treatment assignment until hospital day 30	Same as for target trial
Estimation	Intention-to-treat and per-protocol effects	Intention-to-treat effect

Abbreviations: RRT, renal replacement therapy; CLABSI, central-line associated bloodstream infection; CAUTI, catheter associated urinary tract infection; SSI, surgical site infection; VAP, ventilator associated pneumonia

Variable	Description
Treatment	
Treated	Patients receiving IMV (any invasive ventilation), RRT (any acute continuous renal replacement method), or VP ((nor-)epinephrine, phenylephrine, or vasopressin) within the eligibility period of the first 24 hours (72 hours for RRT) of their ICU stay
Controls	Patients receiving no IMV, RRT, or VP during their ICU stay, or after the end of the eligibility period
Outcomes	
Primary: In-hospital death or discharge to hospice	As provided by dataset
Secondary: Hospital-free days by day 28, nosocomial infection, RBC transfusion within 1 st 24h	Secondary: hospital-free days by day 28 calculated by 28 minus length of stay, set to 0 in case of death Nosocomial infections (CLABSI, CAUTI, SSI, VAP), ascertained by billing codes, see below
CAUTI	ICD-10 code T83.511
CLABSI	ICD-10 code T80.211
SSI	ICD-10 code T81.4
VAP	ICD-10 code J95.851
Covariates	
Age	At admission
Sex	As provided by dataset
Ethnicity	0 if Racial-ethnic group (self-reported), 1 if White
Insurance	As provided by dataset, Medicare/Medicaid or other

<u>eTable 2</u>: Variables used in the analysis to adjust the TMLE models.

Year group	As provided by dataset, bi-yearly bins
Elective admission	Admission categorized as 'ELECTIVE', or 'SURGICAL SAME DAY ADMISSION'
Surgery during admission	As provided by the OASIS score
Coding status	Binary, full code on admission and upon discharge
SOFA	SOFA score on admission with each of its subcomponents
Charlson comorbidity index	As provided by dataset
Fluids	Sum of the volume administered during the whole ICU stay
Vital signs	Respiratory rate, heart rate, mean blood pressure, temperature, and SpO_2 ; Mean during the first 24 hours
Laboratory values	Minimum value during the first 24 hours: Sodium, pH, p_aO_2 , fibrinogen
	Minimum value during the whole stay: Cortisol, hemoglobin
	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, p_aCO_2
Hypertension	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, p_aCO_2 ICD-10 codes I11.X-I16X and I.70X
Hypertension Congestive heart failure	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, p _a CO ₂ ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X
Hypertension Congestive heart failure COPD	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, paCO ₂ ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X ICD-10 codes J41.X-J47.X
Hypertension Congestive heart failure COPD Asthma	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, paCO ₂ ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X ICD-10 codes J41.X-J47.X ICD-10 codes J84.1X
Hypertension Congestive heart failure COPD Asthma Coronary artery disease	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, paCO ₂ ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X ICD-10 codes J41.X-J47.X ICD-10 codes J84.1X ICD-10 codes I20.X-I25.X
Hypertension Congestive heart failure COPD Asthma Coronary artery disease Chronic kidney disease	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, paCO ₂ ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X ICD-10 codes J41.X-J47.X ICD-10 codes J84.1X ICD-10 codes I20.X-I25.X ICD-10 codes N18.1X-N18.6X
Hypertension Congestive heart failure COPD Asthma Coronary artery disease Chronic kidney disease Diabetes type	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, paCO ₂ ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X ICD-10 codes J41.X-J47.X ICD-10 codes J84.1X ICD-10 codes I20.X-I25.X ICD-10 codes N18.1X-N18.6X ICD-10 codes E08.X-E11.X, and E13.X
Hypertension Congestive heart failure COPD Asthma Coronary artery disease Chronic kidney disease Diabetes type Connective tissue disease	Maximum value during the first 24 hours: Glucose, potassium, INR, lactate, paCO2 ICD-10 codes I11.X-I16X and I.70X ICD-10 codes I50.X, I11.0X, I27.X, I42.X, I43.X, I51.7X ICD-10 codes J41.X-J47.X ICD-10 codes J41.X-J47.X ICD-10 codes J41.X-J47.X ICD-10 codes J84.1X ICD-10 codes I20.X-I25.X ICD-10 codes I20.X-I25.X ICD-10 codes N18.1X-N18.6X ICD-10 codes E08.X-E11.X, and E13.X ICD-10 codes L94.0X, L94.1X, L94.3X, M05.X, M06.X, M08.X, M12.0X, M12.3X, M30.X-M31.3X, M32.X-M35.X, M45, M46.1X, M46.8X, or M46.9X

Urinary tract infection on admission	ICD codes N30.0X, or N39.0X if listed among top 3 diagnoses by billing department
Biliary tract infection on admission	ICD codes K81.X, K83.0X, or K85.1X if listed among top 3 diagnoses by billing department
Skin infection on admission	ICD codes L0X.X if listed among top 3 diagnoses by billing department

Abbreviations: IMV, invasive mechanical ventilation; RRT, renal replacement therapy; VP, vasopressor; CLABSI, central-line associated bloodstream infection; CAUTI, catheter associated urinary tract infection; SSI, surgical site infection; VAP, ventilator associated pneumonia; SOFA, Sequential Organ Failure Assessment; OASIS, Oxford Acute Severity of Illness Score; COPD, chronic obstructive pulmonary disease

Primary Outcome Mortality	Survived				Died			Survived Died			
Predicted Mortality	0 - 6	7 - 11	12 - 21	> 21	0 - 6	7 - 11	12 - 21	> 21			
Ranges (%)	(N=4,165)	(N=4,575)	(N=4,003)	(N=3,146)	(N=329)	(N=688)	(N=911)	(N=1,602)			
Treatment		-			-	-	-				
Invasive mechanical ventilation	410	1,701	2,269	2,449	13	164	355	1,189			
	(9.8%)	(37.2%)	(56.7%)	(77.8%)	(4.0%)	(23.8%)	(39.0%)	(74.2%)			
Renal replacement therapy	165	193	211	330	41	56	94	274			
	(4.0%)	(4.2%)	(5.3%)	(10.5%)	(12.5%)	(8.1%)	(10.3%)	(17.1%)			
Vasopressor(s)	1,466	1,761	1,849	1,801	78	211	397	1,073			
	(35.2%)	(38.5%)	(46.2%)	(57.2%)	(23.7%)	(30.7%)	(43.6%)	(67.0%)			
Race-ethnicity											
Racial-ethnic group	761	811	691	569	63	122	164	315			
	(18.3%)	(17.7%)	(17.3%)	(18.1%)	(19.1%)	(17.7%)	(18.0%)	(19.7%)			
White group	3,404	3,764	3,312	2,577	266	566	747	1,287			
	(81.7%)	(82.3%)	(82.7%)	(81.9%)	(80.9%)	(82.3%)	(82.0%)	(80.3%)			

<u>eTable 3</u>: Positivity of mortality for every mortality probability, treatment, and race-ethnicity, to check for violations of the positivity assumption.

Average tre (95	atment effect* i% CI)	Predicted Mortality Ranges (%)								
		0	0 - 6 7 - 11 12 - 21			>:	21			
Treatment	atment Outcome RI per Race- Ethnicity		WG	REG	WG	REG	WG	REG	WG	
Invasive mechanical ventilation	In-hospital mortality	2.0% (0.0% to 4.0%)	-2.0% (-3.0% to -1.0%)	1.0% (-1.0% to 3.0%)	0.0% (-1.0% to 1.0%)	-2.0% (-5.0% to 1.0%)	-3.0% (-4.0% to -1.0%)	-2.0% (-5.0% to 2.0%)	3.0% (1.0% to 4.0%)	
	Hospital free days	-0.57 (-1.05 to -0.08)	-0.43 (-0.64 to -0.23)	-1.07 (-1.62 to -0.53)	-0.56 (-0.83 to -0.3)	-0.37 (-1.09 to 0.35)	-0.07 (-0.39 to 0.26)	-0.13 (-0.86 to 0.59)	-0.91 (-1.38 to -0.44)	
-	Nosocomial infections	0.0 (0.0% t	0% :o 0.0%)	0.0% (0.0% to 0.0%)		0.0% (0.0% to 1.0%)		0.0 (0.0% t)% o 1.0%)	
-	Odd hour discharge or death	Odd hour2.0%scharge or(-7.0% to 3.0%)death		0.0 (-3.0% t	0.0% (-3.0% to 3.0%)		1.0% (-1.0% to 4.0%)		1.0% (-3.0% to 4.0%)	
RRT	In-hospital mortality	5.0% (2.0% to 7.0%)	-2.0% (-5.0% to 2.0%)	-2.0% (-4.0% to 0.0%)	6.0% (5.0% to 7.0%)	5.0% (2.0% to 7.0%)	0.0% (-1.0% to 1.0%)	-1.0% (-5.0% to 3.0%)	3.0% (2.0% to 4.0%)	
-	Hospital free days	-0.87 (-1.47 to -0.26)	-1.84 (-2.05 to -1.63)	-0.1 (-0.63 to 0.42)	-0.39 (-0.63 to -0.16)	1.39 (0.66 to -0.16)	-0.79 (-1.09 to -0.49)	1.39 (0.66 to 2.12)	-0.4 (-0.77 to -0.04)	
	Nosocomial infections	0.0 (0.0% 1	0% co 0.0%)	0.0 (0.0% t	0.0% 0.0% (-1.0%) 0.0%		0.0% (-1.0% to 0.0%)		0.0% (0.0% to 1.0%)	
-	Odd hour discharge or death	3.0 (-3.0% 1	3.0% -4.0% -5.0% (-3.0% to -9.0%) (-10.0% to 2.0%) (-11.0% to 0.0%)		-4.0% -5.0% (-10.0% to 2.0%) (-11.0% to 0.0%)		-5.0% (-11.0% to 0.0%)		-3.0% (-7.0% to 1.0%)	
Vaso- pressors	In-hospital mortality	2.0% (-1.0% to 4.0%)	-2.0% (-3.0% to -1.0%)	0.0% (-3.0% to 2.0%)	0.0% (-1.0% to 1.0%)	-3.0% (-6.0% to 0.0%)	1.0% (-1.0% to 2.0%)	2.0% (-2.0% to 7.0%)	1.0% (-1.0% to 3.0%)	
	Hospital free days	-0.11 (-0.63 to 0.41)	0.76 (0.54 to 0.98)	-0.06 (-0.66 to 0.53)	0.1 (-0.17 to 0.36)	0.31 (-0.55 to 1.16)	0.02 (-0.43 to 0.48)	-0.48 (-1.56 to 0.59)	-0.43 (-1 to 0.13)	
-	Nosocomial infections	0.0 (0.0% 1	0% to 0.0%)	0.0 (0.0% t	0.0% (0.0% to 0.0%)		0.0% (0.0% to 0.0%)		9% o 0.0%)	
	Odd hour discharge or death	0.0 (-3.0%	0% to 3.0%)	2.0% (-1.0% to 5.0%)		0.0% (-3.0% to 3.0%)		-1.0% (-4.0% to 2.0%)		

<u>eTable 4</u>: Primary and secondary outcomes using targeted maximum likelihood estimation.

Legend: *Average treatment effect is in percentages of increase in outcome if treated for binary outcomes, and in absolute mean days for continuous outcomes. Predicted mortality was calculated from OASIS score.

Abbreviations: CI, confidence interval at 95%; OASIS, Oxford Acute Severity of Illness Score



eFigure 1a: Distribution of patients across predicted mortality ranges, per invasive treatment for Racial-ethnic group only.

eFigure 1b: Distribution of patients across predicted mortality ranges, per invasive treatment for White group only.



Likelihood of Receiving a Treatment, per Outcome

Abbreviations: RRT, renal replacement therapy

eFigure 2a: TMLE derived average treatment effects for change in probability of death over predicted mortality categories with an eligibility period for RRT of 1 day instead of 3 days.



TMLE for in-hospital mortality for each invasive treatment

Predicted mortality (%)

eFigure 2b: TMLE derived average treatment effects for change in probability of death over predicted mortality categories with an eligibility period for RRT of 5 days instead of 3 days.



TMLE for in-hospital mortality for each invasive treatment





eFigure 3: TMLE derived average treatment effects for change in mean hospital-free days over predicted mortality categories.

Abbreviations: ATE, average treatment effects; TMLE, targeted maximum likelihood; RRT, renal replacement therapy